147 related articles for article (PubMed ID: 29720732)
21. Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation.
Peiris MN; Meyer AN; Warda D; Campos AR; Donoghue DJ
Oncotarget; 2022; 13():659-676. PubMed ID: 35574218
[TBL] [Abstract][Full Text] [Related]
22. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
[TBL] [Abstract][Full Text] [Related]
23. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.
Xiao S; Nalabolu SR; Aster JC; Ma J; Abruzzo L; Jaffe ES; Stone R; Weissman SM; Hudson TJ; Fletcher JA
Nat Genet; 1998 Jan; 18(1):84-7. PubMed ID: 9425908
[TBL] [Abstract][Full Text] [Related]
24. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.
Verstovsek S; Subbiah V; Masarova L; Yin CC; Tang G; Manshouri T; Asatiani E; Daver NG
Ann Oncol; 2018 Aug; 29(8):1880-1882. PubMed ID: 29767670
[No Abstract] [Full Text] [Related]
25. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
Fioretos T; Panagopoulos I; Lassen C; Swedin A; Billström R; Isaksson M; Strömbeck B; Olofsson T; Mitelman F; Johansson B
Genes Chromosomes Cancer; 2001 Dec; 32(4):302-10. PubMed ID: 11746971
[TBL] [Abstract][Full Text] [Related]
26. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).
Wasag B; Lierman E; Meeus P; Cools J; Vandenberghe P
Haematologica; 2011 Jun; 96(6):922-6. PubMed ID: 21330321
[TBL] [Abstract][Full Text] [Related]
27. Distinct signaling programs associated with progression of FGFR1 driven leukemia in a mouse model of stem cell leukemia lymphoma syndrome.
Silva J; Chang CS; Hu T; Qin H; Kitamura E; Hawthorn L; Ren M; Cowell JK
Genomics; 2019 Dec; 111(6):1566-1573. PubMed ID: 30439482
[TBL] [Abstract][Full Text] [Related]
28. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
29. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
30. The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein.
Jin Y; Zhen Y; Haugsten EM; Wiedlocha A
Cell Signal; 2011 Nov; 23(11):1758-66. PubMed ID: 21745565
[TBL] [Abstract][Full Text] [Related]
31. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
Malchers F; Dietlein F; Schöttle J; Lu X; Nogova L; Albus K; Fernandez-Cuesta L; Heuckmann JM; Gautschi O; Diebold J; Plenker D; Gardizi M; Scheffler M; Bos M; Seidel D; Leenders F; Richters A; Peifer M; Florin A; Mainkar PS; Karre N; Chandrasekhar S; George J; Silling S; Rauh D; Zander T; Ullrich RT; Reinhardt HC; Ringeisen F; Büttner R; Heukamp LC; Wolf J; Thomas RK
Cancer Discov; 2014 Feb; 4(2):246-57. PubMed ID: 24302556
[TBL] [Abstract][Full Text] [Related]
32. A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation.
Morishige S; Oku E; Takata Y; Kimura Y; Arakawa F; Seki R; Imamura R; Osaki K; Hashiguchi M; Yakushiji K; Mizuno S; Yoshimoto K; Nagafuji K; Ohshima K; Okamura T
Acta Haematol; 2013; 129(2):83-9. PubMed ID: 23171834
[TBL] [Abstract][Full Text] [Related]
33. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution.
Patnaik MM; Gangat N; Knudson RA; Keefe JG; Hanson CA; Pardanani A; Ketterling RP; Tefferi A
Am J Hematol; 2010 Apr; 85(4):238-42. PubMed ID: 20143402
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy and disease monitoring in CNTRL-FGFR1-driven leukaemia.
Brown LM; Bartolo RC; Davidson NM; Schmidt B; Brooks I; Challis J; Petrovic V; Khuong-Quang DA; Mechinaud F; Khaw SL; Majewski IJ; Oshlack A; Ekert PG
Pediatr Blood Cancer; 2019 Oct; 66(10):e27897. PubMed ID: 31250523
[TBL] [Abstract][Full Text] [Related]
35. [Inhibitory Eefects of the novel tyrosine kinase inhibitor BGJ398 against human leukemic cell line KG-1 cells].
Jiang Y; Chao HY; Zhang XW; Zhou M; Lu XZ; Zhang R; He C; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):143-147. PubMed ID: 29562450
[No Abstract] [Full Text] [Related]
36. Molecular identification of a TPR-FGFR1 fusion transcript in an adult with myeloproliferative neoplasm, T-lymphoblastic lymphoma, and a t(1;8)(q25;p11.2).
Kim SY; Kim JE; Park S; Kim HK
Cancer Genet; 2014 Jun; 207(6):258-62. PubMed ID: 25037443
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome.
Delaval B; Létard S; Lelièvre H; Chevrier V; Daviet L; Dubreuil P; Birnbaum D
Cancer Res; 2005 Aug; 65(16):7231-40. PubMed ID: 16103074
[TBL] [Abstract][Full Text] [Related]
38. Molecular monitoring of 8p11 myeloproliferative syndrome in an infant.
Zhang WW; Habeebu S; Sheehan AM; Naeem R; Hernandez VS; Dreyer ZE; López-Terrada D
J Pediatr Hematol Oncol; 2009 Nov; 31(11):879-83. PubMed ID: 19829149
[TBL] [Abstract][Full Text] [Related]
39. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase.
Ren M; Li X; Cowell JK
Blood; 2009 Aug; 114(8):1576-84. PubMed ID: 19506298
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
Nakamura S; Yokota D; Tan L; Nagata Y; Takemura T; Hirano I; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
Int J Cancer; 2012 Mar; 130(5):1046-59. PubMed ID: 21400515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
